Detalhe da pesquisa
1.
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
Rheumatology (Oxford)
; 57(5): 900-908, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29415145
2.
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
J Rheumatol
; 49(2): 133-141, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34526397
3.
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Lancet Respir Med
; 10(4): 327-336, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35123660
4.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Lancet Respir Med
; 9(12): 1407-1418, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480861
5.
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
Arthritis Res Ther
; 21(1): 102, 2019 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30999933
6.
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
Rheumatol Ther
; 5(1): 43-55, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29680881